On November 12, Hangzhou Yili Pharmaceutical Co., Ltd. announced the completion of Series A financing of nearly 400 million yuan. This round of financing was led by Huagai Capital, co-led by Kangjun Capital, Boyu Venture Capital, German Union Capital, Xincheng Fund, Haibang Investment, Borui Capital, Shenzhen Angel, and Yuanyi Investment. The original shareholders Shiyao Guofang Pilot Fund, Weige Capital, Xineng Venture Capital, Longfeng Venture Capital, Hongsheng Capital, Shell Fund, and Honghou Investment continued to increase.

Zhitongcaijing · 2d ago
On November 12, Hangzhou Yili Pharmaceutical Co., Ltd. announced the completion of Series A financing of nearly 400 million yuan. This round of financing was led by Huagai Capital, co-led by Kangjun Capital, Boyu Venture Capital, German Union Capital, Xincheng Fund, Haibang Investment, Borui Capital, Shenzhen Angel, and Yuanyi Investment. The original shareholders Shiyao Guofang Pilot Fund, Weige Capital, Xineng Venture Capital, Longfeng Venture Capital, Hongsheng Capital, Shell Fund, and Honghou Investment continued to increase.